Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Rauch

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Kathryn P Gray, Shari Gelber, et al.
Oral Oncology|August 27, 2019
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert Haddad, Joel Guigay, Ulrich Keilholz, et al.
Breast (Edinburgh, Scotland)|July 13, 2024
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancerEleonora Pagan, Monica Ruggeri, Nadia Bianco, et al.
Journal of Cancer Survivorship : Research and Practice|June 10, 2022
Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and SwitzerlandKarin Ribi, Eleonora Pagan, Isabella Sala, et al.
Blood Advances|January 30, 2025
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year updateEva Kimby, Sämi Schär, Maria Cristina Pirosa, et al.
Blood|May 19, 2019
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyEmanuele Zucca, Stephanie Rondeau, Anna Vanazzi, et al.
JAMA Oncology|June 14, 2019
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialBarbara Burtness, Robert Haddad, José Dinis, et al.
The Lancet. Respiratory Medicine|April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Urania Dafni, Enriqueta Felip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2016
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung TrialSolange Peters, Rolf A Stahel, Urania Dafni, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Kathryn P Gray, Shari Gelber, et al.
Oral Oncology|August 27, 2019
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert Haddad, Joel Guigay, Ulrich Keilholz, et al.
Breast (Edinburgh, Scotland)|July 13, 2024
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancerEleonora Pagan, Monica Ruggeri, Nadia Bianco, et al.
Journal of Cancer Survivorship : Research and Practice|June 10, 2022
Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and SwitzerlandKarin Ribi, Eleonora Pagan, Isabella Sala, et al.
Blood Advances|January 30, 2025
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year updateEva Kimby, Sämi Schär, Maria Cristina Pirosa, et al.
Blood|May 19, 2019
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyEmanuele Zucca, Stephanie Rondeau, Anna Vanazzi, et al.
JAMA Oncology|June 14, 2019
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialBarbara Burtness, Robert Haddad, José Dinis, et al.
The Lancet. Respiratory Medicine|April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Urania Dafni, Enriqueta Felip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2016
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung TrialSolange Peters, Rolf A Stahel, Urania Dafni, et al.
Pageof 6